Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Samuel Lunenfeld Research Institute, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.
Clin Proteomics. 2013 May 1;10(1):5. doi: 10.1186/1559-0275-10-5.
Alzheimer's disease (AD) is the most common type of dementia affecting people over 65 years of age. The hallmarks of AD are the extracellular deposits known as amyloid β plaques and the intracellular neurofibrillary tangles, both of which are the principal players involved in synaptic loss and neuronal cell death. Tau protein and Aβ fragment 1-42 have been investigated so far in cerebrospinal fluid as a potential AD biomarkers. However, an urgent need to identify novel biomarkers which will capture disease in the early stages and with better specificity remains. High-throughput proteomic and pathway analysis of hippocampal tissue provides a valuable source of disease-related proteins and biomarker candidates, since it represents one of the earliest affected brain regions in AD.
In this study 2954 proteins were identified (with at least 2 peptides for 1203 proteins) from both control and AD brain tissues. Overall, 204 proteins were exclusively detected in AD and 600 proteins in control samples. Comparing AD and control exclusive proteins with cerebrospinal fluid (CSF) literature-based proteome, 40 out of 204 AD related proteins and 106 out of 600 control related proteins were also present in CSF. As most of these proteins were extracellular/secretory origin, we consider them as a potential source of candidate biomarkers that need to be further studied and verified in CSF samples.
Our semiquantitative proteomic analysis provides one of the largest human hippocampal proteome databases. The lists of AD and control related proteins represent a panel of proteins potentially involved in AD pathogenesis and could also serve as prospective AD diagnostic biomarkers.
阿尔茨海默病(AD)是最常见的痴呆症类型,影响 65 岁以上的人群。AD 的特征是细胞外沉积的淀粉样β斑块和细胞内的神经原纤维缠结,这两者都是导致突触丧失和神经元细胞死亡的主要因素。迄今为止,在脑脊液中已经研究了tau 蛋白和 Aβ 片段 1-42 作为潜在的 AD 生物标志物。然而,仍然迫切需要确定新的生物标志物,以便在早期阶段更好地特异性地捕获疾病。对海马组织进行高通量蛋白质组学和途径分析提供了与疾病相关的蛋白质和生物标志物候选物的有价值的来源,因为它是 AD 最早受影响的大脑区域之一。
在这项研究中,从对照和 AD 脑组织中鉴定出了 2954 种蛋白质(至少有 1203 种蛋白质有 2 种肽)。总的来说,204 种蛋白质仅在 AD 中检测到,600 种蛋白质在对照样本中检测到。将 AD 和对照的特有蛋白与脑脊液(CSF)文献中的蛋白质组进行比较,在 204 种 AD 相关蛋白中有 40 种和 600 种对照相关蛋白中有 106 种也存在于 CSF 中。由于这些蛋白质大多数是细胞外/分泌来源的,我们认为它们是候选生物标志物的潜在来源,需要在 CSF 样本中进一步研究和验证。
我们的半定量蛋白质组学分析提供了最大的人类海马体蛋白质组数据库之一。AD 和对照相关蛋白的列表代表了一组潜在参与 AD 发病机制的蛋白质,也可以作为 AD 诊断的潜在生物标志物。